Incremental value of contrast myocardial perfusion to detect intermediate versus severe coronary artery stenosis during stress-echocardiography

All patients who were clinically indicated elective coronary angiography between March 2008 and January 2009 for a recent chest pain syndrome were asked their informed consent to be enrolled in the study; the ones who consented underwent DASE within 2 weeks before coronary angiography, in the absence of the following exclusion criteria:

The contrast stress protocol is shown in Figure 1. All images were acquired in the apical 4, 2 and 3 chamber views using S5 broadband transducer (Philips, Eindhoven, Netherlands). Wall motion and myocardial perfusion were assessed at rest and at peak stress. Sonovue (Bracco, Milan, Italy) was infused using a rotating pump (BR-NF100, Bracco, Geneva, Switzerland) at rest and 1 minute after completion of dipyridamole infusion. Low power (0.10) continuous imaging was performed for WM assessment. For MPI image acquisition a flash-replenishment sequence (destructive pulse of 8 frames at a mechanical index of 1.0, followed by low power imaging for 10 cycles) was used both in the continuous (40 frames/sec) and triggered mode (end-systolic at every cardiac cycle) [5].

Care was taken to opacify the left ventricle and the myocardium homogeneously with minimization of attenuation so that it is confined to the atrium prior to acquisition of contrast imaging. To achieve this the infusion rate and gain settings are adjusted (e.g. if the contrast attenuation is seen in the LV cavity, infusion rate is reduced and if the attenuation is optimal, then gains are increased for optimal opacification). Gain settings are considered optimal if the destructive impulses result in complete clearance of microbubbles from the myocardium with very little cavity contrast destruction.

Quantitative coronary angiography (QCA) was performed by a cardiologist (F.U.), unaware of the echocardiography results. Any evident stenosis was measured (Qangio XA version 7.0, Medis, Leiden, the Netherlands) and expressed as percent narrowing using the nearest normal-appearing region as the reference. An intermediate stenosis was defined as luminal stenosis in one or more coronary arteries or major branches between 50% and 70%, while a severe stenosis was defined as > 70% narrowing.

Patients were divided into subgroups: a) normal coronaries or < 50% stenosis, b) stenosis between 50% and 70% as the worst coronary lesion (INTERMEDIATE group) or c) at least one > 70% stenosis (SEVERE group). Patients with left main disease ≥50% were also included in the SEVERE group. Multivessel disease was defined when more than one of the three major coronary arteries (or left main trunk) was affected by a ≥50% stenosis. Coronary territories were assigned according to guidelines [11].

169 consecutive patients met the inclusion criteria; 11 denied informed consent and 8 met exclusion criteria (6 insufficiently echogenic and 2 reporting known allergy to sulfonamides). 150 patients were finally enrolled. Mean age was 70 ± 9, 78 (52%) were males, 115 (77%) had at least 2 traditional risk factors for CAD, 40 (27%) had diabetes mellitus and 51 (34%) had a previous myocardial infarction or percutaneous coronary intervention; 47 subjects (31%) had a final angiographic result of single vessel-disease, 55 (37%) multivessel, while 48 (32%) had normal or < 50% stenosed coronary arteries. All demographic and clinical data were comparable between the INTERMEDIATE and the SEVERE group.

The prevalence of reversible WM abnormalities was higher in the SEVERE group when compared with the INTERMEDIATE group (p < 0.001); in contrast, the prevalence of MPI abnormalities was not different between the two groups (Table 1).

Sensitivity, specificity and accuracy for WM and WM+MPI in patients with any stenosis ≥ 50% (INTERMEDIATE+SEVERE groups) or > 70% only (SEVERE group) are reported in Figure 2, along with sensitivity data for the INTERMEDIATE group.

Sensitivity using WM+MPI resulted significantly higher than using WM data only, whatever the cut-off used to define CAD. The sensitivity increase was highest in the INTERMEDIATE group, from 37% (CI 25%-47%) to 98% (CI 89%-100%), (p < 0.001).

The sensitivity increase of WM+MPI for CAD ≥50%, from 66% (CI 61%-70%) to 96% (CI 92%-99%) (p < 0.001), was only partially counterbalanced by the specificity decrease from 83% (CI 70%-92%) to 69% (CI 61%-74%) (p < 0.05); MPI total accuracy resulted higher compared with standalone WM analysis, 87% (CI 82%-93) vs 71% (CI 65%-78%), (p < 0.001). On the contrary, in the SEVERE group the decrease in specificity obtained with the addition of MPI data was much higher, from 74% (CI 67%-79%) to 38% (CI 29%-49%, p < 0.001), than the sensitivity increase, from 85% (CI 76%-91%) to 96% (CI 92%-99%), p < 0.05), with final lower total accuracy, from 79% (CI 72%-83%) to 61% (54-65) (p < 0.001).

The addition of MPI identified 25 more true positive patients than WM in the INTERMEDIATE group; among them, in 13 patients (52%) the intermediate stenosis detected was in the anterior circulation (anterior descending coronary artery), in 10 patients (40%) in the posterior circulation (right or circumflex coronary artery) and in 2 patients (8%) both in the anterior and posterior circulation.

The addition of MPI identified 6 more true positive patients than WM in the SEVERE group, 5 with stenosis both in the anterior and posterior circulation (multivessel disease) and 1 with a single stenosis in the anterior circulation (single-vessel disease).

Figure 3 shows the average stenosis diameter in patients who underwent QCA, classified into three subgroups based on SE results: MPI-/WM-, MPI+/WM-, MPI+/WM+.

Figure 4 shows a typical DASE examination resulting positive for MPI after dipyridamole with normal peak WM, in a patient finally diagnosed with two-vessel 50%-70% coronary artery stenosis (see also Additional File 1).

The intraobserver agreement on the presence or absence of reversible visual MPI or WM abnormality after dipyridamole is respectively 97% (Kappa = 0.91) and 100% (Kappa = 1); the interobserver agreement data is respectively 93% (Kappa = 0.83) and 90% (Kappa = 0.73).

The test could be performed and interpreted both for WM and MPI in all enrolled patients, after the initial exclusion of 8 patients for poor acoustic windows or sulfonamide allergy. Feasibility of DASE was consequently 95%.

After dipyridamole infusion mild flushing or headache were commonly reported. There were no serious or irreversible adverse events. There was no suggestion for any direct adverse effect related to contrast infusion.

An intermediate stenosis has a negative prognostic impact on future cardiac events only if associated with a reduced coronary (CFR) or fractional flow reserve (FFR); CFR or FFR have been found reduced in more than half of patients with known intermediate stenosis, non-invasively studied using stress-echocardiography (CFR assessment), or invasively studied with Doppler flow-wire measurements (FFR assessment) [2, 4]. The detection of an intermediate stenosis may consequently be relevant for the clinical prognosis of patients, although the management of such intermediate stenosis needs to be tailored on a single patient basis.

The long-term prognostic value of MPI for hard cardiac events, independently by WM, has been clearly demonstrated [12, 13], however no single study specifically addressed the prognostic value of a MPI defect subtended by an intermediate stenosis.

In conclusion, whether a reversible perfusion defect in patients with isolated intermediate stenosis implies an unfavorable prognosis is a question that remains unanswered.

Contemporary studies using either dipyridamole or dobutamine echocardiography clearly demonstrated the suboptimal sensitivity of pharmacologic stress protocols to detect intermediate stenosis when using standard WM criteria [1, 2, 14, 15]. In a study using MPI in conjunction with dobutamine-atropine SE, pooled sensitivity of WM criteria for intermediate stenosis was only 30%, increasing to 67% when MPI was added [1].

A recent study, in which high dose dipyridamole was used, reported a 20% sensitivity for WM criteria to detect 50%-75% coronary stenosis in patients with isolated intermediate stenosis of the anterior descending coronary artery; transthoracic Doppler CFR in this study was very effective to overcome the limited sensitivity of WM, but in the clinical practice the undisputable value of non-invasive CFR measurement is technically limited to the anterior coronary circulation [2].

The incremental value of contrast MPI is instead maintained for all coronary territories, as previously reported [1]. In our study the anterior circulation was affected in only 60% of patients with isolated intermediate stenosis.

Another study demonstrated a major step-up in sensitivity for detection of an intermediate stenosis (associated with fractional flow reserve < 0.75) by the use of contrast for left ventricle opacification during dobutamine echocardiography; in this case sensitivity increased from 48% for standard echocardiography without contrast, to 83% with the use of contrast for opacification, reflecting the usefulness of better endocardial border delineation [15].

Sensitivity data in this study, which is otherwise particularly interesting for the choice of a hemodynamic functional endpoint, are presumably much higher than real because of the bias of performing and interpreting the tests in patients with previously known intermediate stenosis, which was the reason for stress-testing.

Contrast use to date is not approved specifically for MPI by the European Medicines Agency (EMEA) and its use remains consequently investigational. In our study contrast MPI is useful to increase the sensitivity of pharmacologic stress-echocardiography when the diagnosis of less severe CAD/stenosis is the diagnostic endpoint, while for more severe CAD/stenosis the profound loss in specificity leads to a significant loss in accuracy, compared with standard WM analysis; whether the diagnostic cost-benefit profile of adding contrast MPI is worth the potential safety issues and contrast-related costs is still a matter of discussion. An isolated MPI abnormality (ie, with normal WM) should not be used as the sole indication to coronary angiography, due to its low specificity for epicardial obstructive CAD.

Patients with a positive provocative test (whatever stress-test considered) and no obstructive epicardial CAD at coronary angiography are usually defined as false-positives. It is now widely recognized that in many different clinical situations (microvascular disease, diffused coronary atherosclerosis, subcritical disease with coronary remodeling, myocardial bridges, coronary spasm, cardiomyopathies and others) coronary blood flow under stress condition may be significantly reduced in the absence of epicardial > 50% stenosis, up to the level capable to cause chest pain, ECG and perfusion abnormalities and, less frequently, WM abnormalities [16]. MPI is intrinsically incline to a higher "false positivity" rate than WM, due to its earlier role in the pathophysiology of the ischemic cascade.

Few stress-echocardiography studies reported that patients with so called "normal coronaries" and an abnormal stress-test (for WM or CFR-LAD) have a worse cardiac prognosis than patients with a normal test [17, 18].

The specificity of WM in our study was lower than reported by several previous studies; this may be due to the non-conservative reading criteria adopted (≥1 segment with new dyssynergy in a region with normal rest function or worsening of rest dyssynergy), that were anyway similarly applied to MPI (≥1 segment with reversible MPI defect). Analysis of echocardiographic data was performed on a patient-basis and not on a territory-basis, since we felt it inappropriate, stress-echocardiograms being always interrupted in our centre at the very first sign of positivity, for safety reasons. The limitations of angiographic comparisons in relation to the discrepancy between stenosis severity and functional significance are pertinent to our study too. Use of angiographic data alone ignores patients with non-ischemic cardiomyopathies, the previous occurrence of coronary events in patients without significant stenosis or microcirculation disease. Wall motion abnormalities or MPI defects in these patients are classified as false-positives; in our experience this has a major impact on MPI data, more than on WM data.